Mahajan, ShiwaniRao, Lokinendi V.Krumholz, Harlan M.2022-08-232022-08-232020-08-062020-08-06<p>medRxiv 2020.08.04.20168203; doi: https://doi.org/10.1101/2020.08.04.20168203. <a href="https://doi.org/10.1101/2020.08.04.20168203" target="_blank" title="View preprint on medRxiv">Link to preprint on medRxiv</a></p>10.1101/2020.08.04.20168203https://hdl.handle.net/20.500.14038/29512<p>This article is a preprint. Preprints are preliminary reports of work that have not been certified by peer review.</p> <p>The PDF available for download is Version 1 of this preprint. The complete version history of this preprint is available at <a href="https://doi.org/10.1101/2020.08.04.20168203" target="_blank" title="View preprint on medRxiv">medRxiv</a>. <a href="https://escholarship.umassmed.edu/faculty_pubs/1822/" target="_blank" title="View Version 2 of preprint in eScholarship@UMMS">Version 2</a> is also available in eScholarship@UMMS.</p> <p>Full author list omitted for brevity. For the full list of authors, see preprint.</p>Importance: A seroprevalence study can estimate the percentage of people with SARS-CoV-2 antibodies in the general population. Most existing reports have used a convenience sample, which may bias their estimates. Objective: To estimate the seroprevalence of antibodies against SARS-CoV-2 based on a random sample of adults living in Connecticut between March 1 and June 1, 2020. Design: Cross-sectional. Setting: We sought a representative sample of Connecticut residents who completed a survey between June 4 and June 23, 2020 and underwent serology testing for SARS-CoV-2-specific IgG antibodies between June 10 and July 6, 2020. Participants: 505 respondents, aged ≥18 years, residing in non-congregate settings who completed both the survey and the serology test. Main outcomes and measures: We estimated the seroprevalence of SARS-CoV-2-specific IgG antibodies among the overall population and across pre-specified subgroups. We also assessed the prevalence of symptomatic illness, risk factors for virus exposure, and self-reported adherence to risk mitigation behaviors among this population. Results: Of the 505 respondents (mean age 50 [±17] years; 54% women; 76% non-Hispanic White individuals) included, 32% reported having at least 1 symptom suggestive of COVID-19 since March 1, 2020. Overall, 18 respondents had SARS-CoV-2-specific antibodies, resulting in the state-level weighted seroprevalence of 3.1 (90% CI 1.4-4.8). Individuals who were asymptomatic had significantly lower seroprevalence (0.6% [90% CI 0.0-1.5]) compared with the overall state estimate, while those who reported having had ≥1 and ≥2 symptoms had a seroprevalence of 8.0% (90% CI 3.1-12.9) and 13.0% (90% CI 3.5-22.5), respectively. All 9 of the respondents who reported previously having a positive coronavirus test were positive for SARS-CoV-2-specific IgG antibodies. Nearly two-third of respondents reported having avoided public places (74%) and small gatherings of family or friends (75%), and 97% reported wearing a mask outside their home, at least part of the time. Conclusions and relevance: These estimates indicate that most people in Connecticut do not have detectable levels of antibodies against SARS-CoV-2. There is a need for continued adherence to risk mitigation behaviors among Connecticut residents, to prevent resurgence of COVID-19 in this region.en-USThe copyright holder for this preprint (which was not peer-reviewed) is the author/funder. It is made available under a CC-BY-NC-ND 4.0 International license.http://creativecommons.org/licenses/by-nc-nd/4.0/COVID-19epidemiologySARS-CoV-2antibodiestestingseroprevalenceConnecticutAmino Acids, Peptides, and ProteinsEpidemiologyImmunology of Infectious DiseaseImmunopathologyInfectious DiseaseVirus DiseasesPreprinthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2752&amp;context=faculty_pubs&amp;unstamped=1https://escholarship.umassmed.edu/faculty_pubs/173518809398faculty_pubs/1735